Citations Report

Clinical Investigation : Citations & Metrics Report

Articles published in Clinical Investigation have been cited by esteemed scholars and scientists all around the world.

Clinical Investigation has got h-index 25, which means every article in Clinical Investigation has got 25 average citations.

Following are the list of articles that have cited the articles published in Clinical Investigation.

• Stothard JR, Stanton MC, Bustinduy AL, Sousa-Figueiredo JC, Van Dam GJ, Betson M, Waterhouse D, Ward S, Allan F, Hassan AA, Al-Helal MA. Diagnostics for schistosomiasis in Africa and Arabia: a review of present options in control and future needs for elimination. Parasitology. 2014 Dec;141(14):1947-61. View at Publisher | View at Google Scholar | View at Indexing
• Topal N, Bozo?lu H. Determination of L-Dopa L-3, 4-dihydroxyphenylalanine Content of Some Faba Bean Vicia faba L. Genotypes. Journal of Agricultural Sciences. 2016 Jan 1;22(2):145-51. View at Publisher | View at Google Scholar | View at Indexing
• Polacsek M, Boardman G, McCann TV. Paying patient and caregiver research participants: putting theory into practice. Journal of Advanced Nursing. 2017 Apr;73(4):847-56. View at Publisher | View at Google Scholar | View at Indexing
• Stamford JA, Schmidt PN, Friedl KE. What engineering technology could do for quality of life in Parkinson's disease: a review of current needs and opportunities. IEEE journal of biomedical and health informatics. 2015 Aug 4;19(6):1862-72. View at Publisher | View at Google Scholar | View at Indexing
• Malaviya AP, Östör AJ.(2012) Rheumatoid arthritis and the era of biologic therapy. Inflammopharmacology;20:59-69. View at Publisher | View at Google Scholar | View at Indexing
• Buyse M, Evans SJ. Fraud in clinical trials. Wiley statsref: statistics reference online. 2014 Apr 14:1-3. View at Publisher | View at Google Scholar | View at Indexing
• Kaufmann J, Feist E, Roske AE, Schmidt WA.(2013) Monotherapy with tocilizumab or TNF-alpha inhibitors in patients with rheumatoid arthritis: efficacy, treatment satisfaction, and persistence in routine clinical practice. Clinical rheumatology;32:1347-1355. View at Publisher | View at Google Scholar | View at Indexing
• George SL, Buyse M. Data fraud in clinical trials. Clinical investigation. 2015;5(2):161. View at Publisher | View at Google Scholar | View at Indexing
• Pope JE, Haraoui B, Thorne JC, Vieira A, Poulin-Costello M, Keystone EC. (2013) The Canadian methotrexate and etanercept outcome study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis. Annals of the rheumatic diseases:annrheumdis. View at Publisher | View at Google Scholar | View at Indexing
• Borland C. Happenings in Hinchingbrooke. Clinical Medicine. 2014 Dec 1;14(6):691-2. View at Publisher | View at Google Scholar | View at Indexing
• Jones G, Darian-Smith E, Kwok M, Winzenberg T.(2012) Effect of biologic therapy on radiological progression in rheumatoid arthritis: what does it add to methotrexate. Biologics ;6:155-161. View at Publisher | View at Google Scholar | View at Indexing
• Simpson R, Layfield C, Williams H. Collaborative clinician-led research networks. Clinical Medicine. 2014 Dec 1;14(6):691-. View at Publisher | View at Google Scholar | View at Indexing
• Ormerod AD, Thomas KS, Craig FE, Mitchell E, Greenlaw N, Norrie J, Mason JM, Walton S, Johnston GA, Williams HC. Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial. bmj. 2015 Jun 12;350. View at Publisher | View at Google Scholar | View at Indexing
• Jones G, Ding C. Tocilizumab (Actemra®). Handbook of Therapeutic Antibodies.:2023-2040. View at Publisher | View at Google Scholar | View at Indexing

• Yang Z, Wang KK (2015) Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker. Trends in neurosciences 38: 364-374.

  View at Publisher | View at Google Scholar
• Iwao Suzuki, and Yasushi Ozeki. "Pharmacological properties and clinical trial results of the synthetic Xa inhibitor fondaparinux sodium (Alixtra ® subcutaneous injection 5 mg, 7.5 mg)." Japan Pharmacological Journal 139.3 (2012): 117-126 .. View at Publisher | View at Google Scholar | View at Indexing

• Johnson JL, Rolan PE, Johnson ME, Bobrovskaya L, Williams DB et al. (2014) Codeine-induced hyperalgesia and allodynia: investigating the role of glial activation. Translational psychiatry 4: e482.

  View at Publisher | View at Google Scholar

• Nazira EH, Rodriguez M, Podhaizer EM, Shiping ZO, Dever SM (2014) Ibudilast (AV411), and its AV1013 analogue, reduce HIV-1 replication and neuronal death induced by HIV-1 and morphine. AIDS (London, England) 28: 1409.

  View at Publisher | View at Google Scholar
• Hron, Gregor, et al. "Alternative diagnosis to heparin-induced thrombocytopenia in two critically ill patients despite a positive PF4/heparin-antibody test." Upsala journal of medical sciences 118.4 (2013): 279-284. View at Publisher | View at Google Scholar | View at Indexing

• Cooper ZD, Johnson KW, Pavlicova M, Glass A, Vosburg SK (2015) The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid‐dependent volunteers. Addiction biology.

  View at Publisher | View at Google Scholar

• Johnson JL, Kwok YH, Sumracki NM, Swift JE, Hutchinson MR et al. (2015) Glial Attenuation With Ibudilast in the Treatment of Medication Overuse Headache: A Double‐Blind, Randomized, Placebo‐Controlled Pilot Trial of Efficacy and Safety. Headache: The Journal of Head and Face Pain 55: 1192-1208.

  View at Publisher | View at Google Scholar

• Andraka-Christou B (2016) Chapter Two-A Pressing Need for Pharmacotherapy Development to Treat Drug Addiction: An Editorial from a Legal Perspective. International review of neurobiology 126: 15-38.

  View at Publisher | View at Google Scholar

• Ray LA, Bujarski S, Shoptaw S, Roche DJ, Heinzerling K et al. (2016) Development of the Neuroimmune Modulator Ibudilast for the Treatment of Alcoholism: A Randomized, Placebo-Controlled, Human Laboratory Trial. Neuropsychopharmacology.

  View at Publisher | View at Google Scholar
• Hatina J. Tumorstammzellen als therapeutisches Ziel der Tumortherapie von morgen. Wiener Medizinische Wochenschrift. 2017 Feb 1;167(1-2):25-30. View at Publisher | View at Google Scholar | View at Indexing
• Greife A, Tukova J, Steinhoff C, Scott SD, Schulz WA, Hatina J. Establishment and characterization of a bladder cancer cell line with enhanced doxorubicin resistance by mevalonate pathway activation. Tumor Biology. 2015 May;36(5):3293-300. View at Publisher | View at Google Scholar | View at Indexing

• Yamashiro Y, Martin J, Gazarian M, Kling S, Nakamura H, Matsui A, Cucchiara S, Aloi M, Wynn EL, Mulberg AE.(2012) Drug development: the use of unlicensed/off-label medicines in pediatrics. Journal of pediatric gastroenterology and nutrition;55:506-510.

  View at Publisher | View at Google Scholar
• De Santis M, Wiechno PJ, Bellmunt J, Lucas C, Su WC, Albiges L, Lin CC, Senkus-Konefka E, Flechon A, Mourey L, Necchi A. Vinflunine–gemcitabine versus vinflunine–carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1). Annals of Oncology. 2016 Mar 1;27(3):449-54. View at Publisher | View at Google Scholar | View at Indexing
• Bellmunt J, Mottet N, De Santis M (2016) Urothelial carcinoma management in elderly or unfit patients. European Journal of Cancer Supplements 14: 1-20. View at Publisher | View at Google Scholar | View at Indexing

• Michael E, Scott D. The Global Pediatric Market and Drivers of Pediatric Drug Development. Pediatric Drug Development: Concepts and Applications.:57-67.

  View at Publisher | View at Google Scholar
• Katolická MJ. Současné postavení chemoterapie v léčbÄ› karcinomu močového mÄ›chýÅ™e. View at Publisher | View at Google Scholar | View at Indexing
• Morelli F (2015) Attività ed efficacia di vinflunina nel carcinoma metastatico della vescica in progressione dopo un trattamento adiuvante: descrizione di un caso clinico. Recenti Progressi in Medicina 106: 300-305. View at Publisher | View at Google Scholar | View at Indexing

• Haas DM. (2014)Pharmacogenetics and individualizing drug treatment during pregnancy. Pharmacogenomics;15:69-78.

  View at Publisher | View at Google Scholar
• Kim ES, Keating GM (2015)Pirfenidone: a review of its use in idiopathic pulmonary fibrosis. Drugs 75: 219-230. View at Publisher | View at Google Scholar | View at Indexing
• Meng H, Xu Y (2015) Pirfenidone-loaded liposomes for lung targeting: preparation and in vitro/in vivo evaluation. Drug design, development and therapy 9:3369. View at Publisher | View at Google Scholar | View at Indexing

• Haas DM, McHugh KW, Durst PJ, Rose SM, Patil AS.(2015) Psychotropic Medications in Pregnancy and the Postpartum Period. Clinical Medicine Insights. Therapeutics ;7:25.

  View at Publisher | View at Google Scholar
• Lv M, Chen Z, Hu G, Li Q. Therapeutic strategies of diabetic nephropathy: recent progress and future perspectives. Drug Discovery Today. 2015 Mar 1;20(3):332-46. View at Publisher | View at Google Scholar | View at Indexing

• Höner zu Siederdissen C, Maasoumy B, Deterding K, Port K, Sollik L et al. (2015) Eligibility and safety of the first interferon‐free therapy against hepatitis C in a real‐world setting. Liver International 35: 1845-1852.

  View at Publisher | View at Google Scholar

• Jencks SF, Williams MV, Coleman EA.(2009) Rehospitalizations among patients in the Medicare fee-for-service program. New England Journal of Medicine;360:1418-1428.

  View at Publisher | View at Google Scholar
• Polacsek M, Boardman G, McCann TV (2016) Paying patient and caregiver research participants: putting theory into practice. Journal of advanced nursing View at Publisher | View at Google Scholar | View at Indexing
• Rolfo C, Caglevic C, Bretel D, Hong D, Raez LE (2016) Cancer clinical research in Latin America: current situation and opportunities. Expert opinion from the first ESMO workshop on clinical trials, Lima, 2015. ESMO open 1: e000055. View at Publisher | View at Google Scholar | View at Indexing
• Lythgoe H, Price V, Poustie V, Attar S, Hawcutt D et al. (2016) NIHR Clinical Research Networks: what they do and how they help paediatric research. Archives of Disease in Childhood View at Publisher | View at Google Scholar | View at Indexing

• Rossi F, Perale G, Papa S, Forloni G, Veglianese P. (2015) Current options for drug delivery to the spinal cord. Expert opinion on drug delivery ;10:385-396.

  View at Publisher | View at Google Scholar
• Berger VW (2015) A Priori v Post Hoc Testing. Encyclopedia of Statistics in Behavioral Science. View at Publisher | View at Google Scholar | View at Indexing

• Simon NG, Turner MR, Vucic S, Al‐Chalabi A, Shefner J, Lomen‐Hoerth C, Kiernan MC.(2014) Quantifying disease progression in amyotrophic lateral sclerosis. Annals of neurology ;76:643-657.

  View at Publisher | View at Google Scholar

• Berger VW, Antsygina O (2015) A review of randomization methods in clinical trials. Clinical Trial Biostatistics and Biopharmaceutical Applications 41-54.

  View at Publisher | View at Google Scholar

• Thomsen GM, Gowing G, Latter J, Chen M, Vit JP, Staggenborg K, Avalos P, Alkaslasi M, Ferraiuolo L, Likhite S, Kaspar BK.(2014) Delayed disease onset and extended survival in the SOD1G93A rat model of amyotrophic lateral sclerosis after suppression of mutant SOD1 in the motor cortex. Journal of Neuroscience ;34:15587-600.

  View at Publisher | View at Google Scholar
• Hirano F, Mizoguchi F, Harigai M, Miyasaka N, Kohsaka H (2015)Tacrolimus successfully used to control refractory eosinophilic granulomatosis with polyangiitis complicated by invasive aspergillosis and chronic hepatitis B. International journal of rheumatic diseases. View at Publisher | View at Google Scholar | View at Indexing

• Berry JD, Miller R, Moore DH, Cudkowicz ME, Van Den Berg LH, Kerr DA, Dong Y, Ingersoll EW, Archibald D. (2013) The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials. Amyotrophic lateral sclerosis and frontotemporal degeneration ;14:162-168.

  View at Publisher | View at Google Scholar

• Balendra R, Jones A, Jivraj N, Steen IN, Young CA, Shaw PJ, Turner MR, Leigh PN, Al-Chalabi A,(2014) UK-MND LiCALS Study Group, Mito Target ALS Study Group. Use of clinical staging in amyotrophic lateral sclerosis for phase 3 clinical trials. Journal of Neurology, Neurosurgery & Psychiatry:jnnp.

  View at Publisher | View at Google Scholar
• Kuchinke W, Ohmann C, Stenzhorn H, Anguista A, Sfakianakis S et al. (2016) J. Ensuring sustainability of software tools and services by cooperation with a research infrastructure. Personalized Medicine 43-55. View at Publisher | View at Google Scholar | View at Indexing

Relevant Topics